Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Junichi Kurebayashi(Kawasaki Medical School), Hiroshi Sonoo(Okayama Prefecture)

BMC Cancer

October 20, 2010

10.1186/1471-2407-10-568

Cited by 43

Related Papers

Anti‐cancer stem cell activity of a hedgehog inhibitor <scp>GANT</scp>61 in estrogen receptor‐positive breast cancer cells

|Cancer Science|2017|44

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

|Breast Cancer|2020|38